The Medicine crisis is likely to worsen in Pakistan after GlaxoSmithKline (GSK) Consumer Healthcare Pakistan on Friday announced to stop production of Panadol Tablets, Panadol Extra Tablets, and Children’s Panadol Liquid.
They were facing heavy financial losses in the production of the Panadol range due to an increase in the price of paracetamol raw ingredients.
According to Pakistan Pharmaceutical Manufacturers Association (PPMA), the cost of medicines has increased by 38 percent due to an increase in the cost of raw materials, rupee devaluation, increase in the cost of utilities as well as transportation charges.
During the last 12 months, the company produced nearly 5,400 million tablets of Panadol 500mg and Panadol Extra to serve its customers, consumers, and patients in need.
The company has played a critical, consumer/patient-focused, and responsible role during the Covid 19 pandemic, and dengue fever crisis.
